Healthcare Business

Investors have flocked to the dividends of Big Pharma and flocked to the limitless upside of major biotech outfits for years. Valuations are no longer considered high for these two healthcare...
Johnson & Johnson has announced that it will launch its human study for its lead vaccine candidate in the United States and Belgium.
Edesa Biotech joins the list of COVID-19 stocks, as the company is making headway with regulatory agencies for its late-stage study. Investors were quick to give this firm the coronavirus bump, more...
Eastman Kodak is making a fresh move to manufacturing drug ingredients with a $765 million government loan under the direction of President Trump.
Spectrum Pharmaceuticals announced good news for lung cancer patients in its midstage trial on Tuesday.
Credit Suisse has assembled its favorite health care recovery stocks for a recovering base of elective surgeries and for the risk of rising hospitalizations that go well beyond COVID-19.
Pfizer released a better than expected second-quarter earnings report and increased its guidance before the markets opened on Tuesday.
Pfizer and BioNTech made another big step in their fight against COVID-19 by initiating their late-stage study for their lead mRNA vaccine candidate.
MediciNova saw the coronavirus bump on Monday after it said it had entered a worldwide exclusive agreement with BioComo for the rights to develop a SARS-CoV-2 vaccine.
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Arbutus Biopharma stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontrunner Moderna.
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of the year.
Pfizer and BioNTech S.E. aim to begin delivering 300 million doses of their vaccine for COVID-19 in 2021, but in the meantime, these companies will get a nice payoff.
The current focus on controlling the COVID-19 pandemic, companies that provide other health care products and services have received less attention from investors and analysts. Here are seven that...